RPD Stock Overview
Operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Royalty Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.55 |
| 52 Week High | US$28.96 |
| 52 Week Low | US$23.44 |
| Beta | 0.46 |
| 1 Month Change | -3.17% |
| 3 Month Change | -4.46% |
| 1 Year Change | -8.90% |
| 3 Year Change | -31.54% |
| 5 Year Change | n/a |
| Change since IPO | -27.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| RPD | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -4.5% | 0.4% | -0.09% |
| 1Y | -8.9% | -12.3% | 9.1% |
Return vs Industry: RPD exceeded the German Pharmaceuticals industry which returned -10.8% over the past year.
Return vs Market: RPD underperformed the German Market which returned 9.6% over the past year.
Price Volatility
| RPD volatility | |
|---|---|
| RPD Average Weekly Movement | 3.3% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: RPD has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: RPD's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Pablo Legorreta | www.royaltypharma.com |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Royalty Pharma plc Fundamentals Summary
| RPD fundamental statistics | |
|---|---|
| Market cap | €14.15b |
| Earnings (TTM) | €1.09b |
| Revenue (TTM) | €2.16b |
9.6x
P/E Ratio4.9x
P/S RatioIs RPD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RPD income statement (TTM) | |
|---|---|
| Revenue | US$2.27b |
| Cost of Revenue | US$491.91m |
| Gross Profit | US$1.77b |
| Other Expenses | US$628.98m |
| Earnings | US$1.15b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.58 |
| Gross Margin | 78.29% |
| Net Profit Margin | 50.53% |
| Debt/Equity Ratio | 74.2% |
How did RPD perform over the long term?
See historical performance and comparison